
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
                                    Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
*本文来源于近日《人民日报》健康客户端刊发的文章,节选如下:...
*近日,《医药经济报》刊发安斯泰来沈阳工厂总经理原田芳行先生的署名文章,全文如下:...
数据显示,研究药物zolbetuximab联合CAPOX与对照组单独使用CAPOX相比,疾病进展或死亡风险降低了31.3% 研究对Claudin...
Read more about 安斯泰来在三月份的美国临床肿瘤学会(ASCO)全体大会系列会议上宣布Zolbetuximab的GLOW III期临床研究积极成果
- 与安慰剂联合雄激素剥夺疗法(ADT)相比,恩扎卢胺联合ADT可显著延缓至前列腺特异性抗原(PSA)进展时间...
- 提交的中国患者临床数据与全球数据一致,并支持了enfortumab...
Read more about 安斯泰来和Seagen宣布中国国家药品监督管理局受理Enfortumab Vedotin用于治疗局部晚期或转移性尿路上皮癌患者的生物制品上市许可申请
